• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
The Genome

Duchenne Muscular Dystrophy (DMD) and Prenatal Carrier Testing

image_pdfFavoriteLoadingFavorite

SUMMARY:

Reproductive carrier screening is an increasingly common practice used to identify pregnancies that are at risk for genetic disorders. Although most carriers are unaffected, carrier status for some conditions can lead to disease symptoms. The DMD gene is associated with X-linked Duchenne (DMD) and Becker (BMD) type muscular dystrophies, which are a spectrum of neuromuscular disorders characterized by progressive muscle weakness and cardiomyopathy. Testing for DMD is frequently offered as part of a reproductive carrier screening panel, even if there is no family history.  Thus, some DMD carriers are identified unexpectedly. These individuals should be aware of potential disease manifestations and understand the recommended surveillance for cardiac disease

BACKGROUND:

  • DMD is included in the ACMG’s “Tier 3” recommendations for carrier screening, which should be offered to all patients who are pregnant or are considering pregnancy (see ‘Related ObG Topics’ below)
    • Patients with a family history of DMD or BMD may require targeted testing, depending on the methods used to detect their familial variant
  • Pathogenic variants in the DMD gene are associated with DMD and BMD type muscular dystrophies
    • These disorders primarily affect males
    • DMD and BMD are distinguished by clinical severity | BMD is used to describe less severe cases with later age of onset
  • DMD and BMD are X-linked. For the offspring of female carriers:
    • Males have a 50% chance to be affected
    • Females have a 50% chance to be carriers

Note: Unlike most disorders on prenatal carrier testing panels which are autosomal recessive, DMD is X-linked | Therefore, testing the reproductive partner of a female carrier is not required to determine risk to the fetus

Symptoms associated with Female Carriers

  • Genetic female (46,XX) DMD carriers are typically asymptomatic, but some experience mild to moderate muscle weakness or cardiac involvement
  • DMD carriers may have the following signs/symptoms
    • Mild/moderate muscle weakness: 14% to 19%
    • Myalgia/cramps: 5%
    • Left ventricle dilation: 16% to 19%
    • Dilated cardiomyopathy: up to 8%
    • Elevated serum creatine kinase (CK) concentration: 30% to 50%

KEY POINTS:

Referrals for Multidisciplinary Care During Pregnancy and Beyond

  • Cardiology  
    • Complete cardiac evaluation and/or cardiac MRI is recommended for female carriers of DMD to assess for dilated cardiomyopathy (DCM), characterized by left ventricular dilation and congestive heart failure
    • Cardiac surveillance should begin in late adolescence/early adulthood
  • Maternal Fetal Medicine
    • Pregnant DMD carriers with cardiac disease should be referred for consultation with a high-risk obstetrician
    • If fetus is male (by ultrasound or NIPS), offer fetal diagnostic testing for DMD via chorionic villus sampling or amniocentesis
  • Genetic Services
    • Educate about risk of developing DCM and/or symptoms of heart failure
    • Counsel about risk to offspring and other family members
      • Male offspring: 50% risk to be affected with BMD or DMD (variant dependent)
      • Female relatives may be carriers with risk for DMD symptoms

Learn More – Primary Sources:

AAP: Cardiovascular Health Supervision for Individuals Affected by Duchenne or Becker Muscular Dystrophy

DMD Care Considerations Working Group: Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management

Gene Reviews: Dystrophinopathies

Locate a Genetic Counselor or Genetics Services: 

Genetic Services Locator-ACMG

Genetic Services Locator-NSGC 

Genetic Services Locator-CAGC 

Locate a Maternal Fetal Medicine Specialist

Maternal Fetal Medicine Specialist Locator-SMFM

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All The Genome Posts
Next >

Related ObG Topics:

ACMG Recommendations for Preconception and Prenatal Carrier Screening

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site